Journal of Clinical Oncology, Vol 12, 2022-2034, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

DC Ihde, JL Mulshine, BS Kramer, SM Steinberg, RI Linnoila, AF Gazdar, M Edison, RM Phelps, M Lesar and JC Phares
National Cancer Institute-Navy Medical Oncology Branch, Uniformed Services University of the Health Sciences, Bethesda, MD.

PURPOSE: We performed a prospective randomized clinical trial to determine whether higher doses of etoposide and cisplatin (EP) yield more complete responses or longer survival in small-cell lung cancer (SCLC) patients. PATIENTS AND METHODS: Ninety patients with previously untreated extensive-stage SCLC fulfilled criteria for randomization to standard-dose versus high-dose EP. Another 25 patients at risk of excessive toxicity from high-dose treatment were given standard-dose therapy. During cycles 1 and 2 of EP, patients on standard-dose treatment received intravenous etoposide 80 mg/m2 on days 1 to 3 and cisplatin 80 mg/m2 on day 1 every 3 weeks; high-dose treatment consisted of etoposide 80 mg/m2 on days 1 to 5 and cisplatin 27 mg/m2 on days 1 to 5 every 3 weeks. All patients received standard-dose EP in cycles 3 and 4. In cycles 5 through 8, completely responding patients continued standard-dose EP; all other patients received either cyclophosphamide, doxorubicin, and vincristine, or (if possible) a combination drug program based on in vitro drug sensitivity testing of tumor-cell lines established from individual patients. RESULTS: Despite 68% higher doses and a 46% higher dose-rate intensity actually given to patients randomized to receive high-dose relative to those randomized to receive standard-dose EP, complete response rates (23% v 22%; P = .99) and median survival durations (10.7 and 11.4 months, respectively; P = .68) were virtually identical. Complete responses occurred in 4% of patients and the median survival duration was 5.8 months in nonrandomized patients. Leukopenia (P < .0001), thrombocytopenia (P < .0001), febrile neutropenia (P = .01), and weight loss (P = .02) were significantly more common in patients randomized to receive high-dose compared with standard-dose EP. CONCLUSION: No therapeutic benefits resulted from increasing planned doses by 67% for the first two cycles of EP in patients with extensive-stage SCLC. Higher doses were associated with substantially worse toxicities.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. K. Demedts, K. Y. Vermaelen, and J. P. van Meerbeeck Treatment of extensive-stage small cell lung carcinoma: current status and future prospects Eur. Respir. J., January 1, 2010; 35(1): 202 - 215. [Abstract] [Full Text] [PDF]

				S. Leyvraz, S. Pampallona, G. Martinelli, F. Ploner, L. Perey, S. Aversa, S. Peters, P. Brunsvig, A. Montes, A. Lange, et al. A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial J Natl Cancer Inst, April 16, 2008; 100(8): 533 - 541. [Abstract] [Full Text] [PDF]

				G A Silvestri and S G Spiro Carcinoma of the bronchus 60 years later Postgrad. Med. J., April 1, 2008; 84(990): 182 - 187. [Full Text] [PDF]

				T. Sher, G. K. Dy, and A. A. Adjei Small Cell Lung Cancer Mayo Clin. Proc., March 1, 2008; 83(3): 355 - 367. [Abstract] [Full Text] [PDF]

				M. O'Brien, J. Eckardt, and R. Ramlau Recent Advances with Topotecan in the Treatment of Lung Cancer Oncologist, October 1, 2007; 12(10): 1194 - 1204. [Abstract] [Full Text] [PDF]

				J. L. Pujol, J. L. Breton, R. Gervais, M.-L. Tanguy, E. Quoix, P. David, H. Janicot, V. Westeel, S. Gameroff, J. Geneve, et al. Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04 IFCT 00-01 J. Clin. Oncol., September 1, 2007; 25(25): 3945 - 3951. [Abstract] [Full Text] [PDF]

				G. Crivellari, S. Monfardini, S. Stragliotto, D. Marino, and S. M. L. Aversa Increasing Chemotherapy in Small-Cell Lung Cancer: From Dose Intensity and Density to Megadoses Oncologist, January 1, 2007; 12(1): 79 - 89. [Abstract] [Full Text] [PDF]

				G A Silvestri and S G Spiro Carcinoma of the bronchus 60 years later. Thorax, December 1, 2006; 61(12): 1023 - 1028. [Full Text] [PDF]

				N. Hanna, P. A. Bunn Jr, C. Langer, L. Einhorn, T. Guthrie Jr, T. Beck, R. Ansari, P. Ellis, M. Byrne, M. Morrison, et al. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer J. Clin. Oncol., May 1, 2006; 24(13): 2038 - 2043. [Abstract] [Full Text] [PDF]

				J. P. Chute, E. Taylor, J. Williams, F. Kaye, D. Venzon, and B. E. Johnson A Metabolic Study of Patients with Lung Cancer and Hyponatremia of Malignancy Clin. Cancer Res., February 1, 2006; 12(3): 888 - 896. [Abstract] [Full Text] [PDF]

				Y. Iwasaki, K. Nagata, M. Nakanishi, A. Natuhara, Y. Kubota, M. Ueda, T. Arimoto, and H. Hara Double-Cycle, High-Dose Ifosfamide, Carboplatin, and Etoposide Followed by Peripheral Blood Stem-Cell Transplantation for Small Cell Lung Cancer Chest, October 1, 2005; 128(4): 2268 - 2273. [Abstract] [Full Text] [PDF]

				H. B. Niell, J. E. Herndon II, A. A. Miller, D. M. Watson, A. B. Sandler, K. Kelly, R. S. Marks, M. C. Perry, R. H. Ansari, G. Otterson, et al. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732 J. Clin. Oncol., June 1, 2005; 23(16): 3752 - 3759. [Abstract] [Full Text] [PDF]

				G. S. Warshamana-Greene, J. Litz, E. Buchdunger, C. Garcia-Echeverria, F. Hofmann, and G. W. Krystal The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy Clin. Cancer Res., February 15, 2005; 11(4): 1563 - 1571. [Abstract] [Full Text] [PDF]

				A. Ardizzoni, A. Favaretto, L. Boni, E. Baldini, F. Castiglioni, P. Antonelli, F. Pari, C. Tibaldi, A. M. Altieri, S. Barbera, et al. Platinum-Etoposide Chemotherapy in Elderly Patients With Small-Cell Lung Cancer: Results of a Randomized Multicenter Phase II Study Assessing Attenuated-Dose or Full-Dose With Lenograstim Prophylaxis--A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) Study J. Clin. Oncol., January 20, 2005; 23(3): 569 - 575. [Abstract] [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]

				E. Galani, P. A. Ellis, and P. G. Harper Small-Cell Lung Cancer, High Growth Rate, High Response Rate to Chemotherapy: Ideal for High-Dose Chemotherapy? J. Clin. Oncol., October 1, 2002; 20(19): 3941 - 3943. [Full Text] [PDF]

				V. C. G. Tjan-Heijnen, D. J. T. Wagener, and P. E. Postmus An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn Ann. Onc., October 1, 2002; 13(10): 1519 - 1530. [Abstract] [Full Text] [PDF]

				A. Ardizzoni, V. C.G. Tjan-Heijnen, P. E. Postmus, E. Buchholz, B. Biesma, H. Karnicka-Mlodkowska, R. Dziadziuszko, J. Burghouts, J. P. van Meerbeeck, S. Gans, et al. Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial--08923 J. Clin. Oncol., October 1, 2002; 20(19): 3947 - 3955. [Abstract] [Full Text] [PDF]

				P. Bunn Reply to "Letter to the Editor on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'", by V. C. G. Tjan-Heijnen, P. E. Postmus & A. Ardizzoni (Ann Oncol 2002; 13: 485-486) Ann. Onc., March 1, 2002; 13(3): 486 - 487. [Full Text] [PDF]

				N. H. Hanna, A. B. Sandler, P. J. Loehrer Sr, R. Ansari, S. H. Jung, K. Lane, and L. H. Einhorn Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study Ann. Onc., January 19, 2002; 13(1): 95 - 102. [Abstract] [Full Text] [PDF]

				J. H. Schiller, S. Adak, D. Cella, R. F. DeVore III, and D. H. Johnson Topotecan Versus Observation After Cisplatin Plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593--A Phase III Trial of the Eastern Cooperative Oncology Group J. Clin. Oncol., April 15, 2001; 19(8): 2114 - 2122. [Abstract] [Full Text] [PDF]

				P. Thomas, O. Castelnau, D. Paillotin, H. Lena, G. Robinet, J. F. Muir, P. Delaval, S. Gouva, P. Balmes, F. Blanchon, et al. Phase II Trial of Paclitaxel and Carboplatin in Metastatic Small-Cell Lung Cancer: A Groupe Francais de Pneumo-Cancerologie Study J. Clin. Oncol., March 1, 2001; 19(5): 1320 - 1325. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, L. L. Muldoon, R. E. Brummett, R. M. Tyson, C. Lacy, J. S. Bubalo, D. F. Kraemer, M. C. Heinrich, J. A. Henry, and E. A. Neuwelt Delayed Sodium Thiosulfate as an Otoprotectant Against Carboplatin-induced Hearing Loss in Patients with Malignant Brain Tumors Clin. Cancer Res., March 1, 2001; 7(3): 493 - 500. [Abstract] [Full Text]

				J.-L. Pujol, J.-P. Daures, A. Riviere, E. Quoix, V. Westeel, X. Quantin, J.-L. Breton, E. Lemarie, M. Poudenx, B. Milleron, et al. Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study J Natl Cancer Inst, February 21, 2001; 93(4): 300 - 308. [Abstract] [Full Text] [PDF]

				G. W. Krystal, S. Honsawek, J. Litz, and E. Buchdunger The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth Clin. Cancer Res., August 1, 2000; 6(8): 3319 - 3326. [Abstract] [Full Text]

				D. H. Johnson Management of Small Cell Lung Cancer* : Current State of the Art Chest, December 1, 1999; 116 (2009): 525S - 530S. [Abstract] [Full Text] [PDF]

				A. Elias Hematopoietic Stem Cell Transplantation for Small Cell Lung Cancer* Chest, December 1, 1999; 116 (2009): 531S - 538S. [Abstract] [Full Text] [PDF]

				S. Leyvraz, L. Perey, G. Rosti, A. Lange, S. Pampallona, R. Peters, Y. Humblet, L. Bosquee, F. Pasini, and M. Marangolo Multiple Courses of High-Dose Ifosfamide, Carboplatin, and Etoposide With Peripheral-Blood Progenitor Cells and Filgrastim for Small-Cell Lung Cancer: A Feasibility Study by the European Group for Blood and Marrow Transplantation J. Clin. Oncol., November 1, 1999; 17(11): 3531 - 3539. [Abstract] [Full Text] [PDF]

				K. Kelly, Z. Pan, M. E. Wood, J. Murphy, and P. A. Bunn Jr. A Phase I Study of Paclitaxel, Etoposide, and Cisplatin in Extensive Stage Small Cell Lung Cancer Clin. Cancer Res., November 1, 1999; 5(11): 3419 - 3424. [Abstract] [Full Text] [PDF]

				D. H. Johnson and D. P. Carbone Increased Dose-Intensity in Small-Cell Lung Cancer: A Failed Strategy? J. Clin. Oncol., August 1, 1999; 17(8): 2297 - 2297. [Full Text] [PDF]

				N. Murray, R. B. Livingston, F. A. Shepherd, K. James, B. Zee, A. Langleben, M. Kraut, J. Bearden, J. W. Goodwin, C. Grafton, et al. Randomized Study of CODE Versus Alternating CAV/EP for Extensive-Stage Small-Cell Lung Cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group J. Clin. Oncol., August 1, 1999; 17(8): 2300 - 2300. [Abstract] [Full Text] [PDF]

				B. S. Glisson, J. M. Kurie, R. Perez-Soler, N. J. Fox, W. K. Murphy, F. V. Fossella, J. S. Lee, M. B. Ross, D. A. Nyberg, K. M.W. Pisters, et al. Cisplatin, Etoposide, and Paclitaxel in the Treatment of Patients With Extensive Small-Cell Lung Carcinoma J. Clin. Oncol., August 1, 1999; 17(8): 2309 - 2309. [Abstract] [Full Text] [PDF]

				B. Jeremic, Y. Shibamoto, N. Nikolic, B. Milicic, S. Milisavljevic, A. Dagovic, J. Aleksandrovic, and G. Radosavljevic-Asic Role of Radiation Therapy in the Combined-Modality Treatment of Patients With Extensive Disease Small-Cell Lung Cancer: A Randomized Study J. Clin. Oncol., July 1, 1999; 17(7): 2092 - 2092. [Abstract] [Full Text] [PDF]

				P. Cortazar and B. E. Johnson Review of the Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1625 - 1625. [Abstract] [Full Text] [PDF]

				A. Elias, J. Ibrahim, A. T. Skarin, C. Wheeler, M. McCauley, L. Ayash, P. Richardson, L. Schnipper, K. H. Antman, and E. Frei III Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome J. Clin. Oncol., April 1, 1999; 17(4): 1175 - 1175. [Abstract] [Full Text] [PDF]

				B. E. JOHNSON, J. P. CHUTE, J. RUSHIN, J. WILLIAMS, P. T. LE, D. VENZON, and G. E. RICHARDSON A Prospective Study of Patients with Lung Cancer and Hyponatremia of Malignancy Am. J. Respir. Crit. Care Med., November 1, 1997; 156(5): 1669 - 1678. [Abstract] [Full Text]